Best Tirzepatide Providers at 7.5mg in 2026: Ranked and Reviewed
A seller reaches this table only by publishing a tirzepatide price at 7.5mg, the therapeutic dose tier. That single filter shortens the list considerably, and it is worth knowing what it hides: a seller may well carry tirzepatide and simply never name this strength on a price page. What you see below is the advertised figure, the date behind it, and our score.
Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more
1 tirzepatide providers compared · independently scored against our six-factor methodology.
Methodology & sources
Each provider here carries a score from our published six-factor rubric[1], and the list is then cut down to the dose named in the page title.
Published Phase 3 efficacy for tirzepatide (~20.9% mean weight loss at the 15 mg dose over 72 weeks) comes from the SURMOUNT-1 trial[2]. The SURMOUNT-5 head-to-head published in 2025 directly compared tirzepatide and semaglutide[3].
The same filter is run at the other doses we rank: 2.5mg, 5mg and 10mg, and brand-name tirzepatide has its own ranking of brand sellers.
Quick Picks
| # | Provider | Score | |
|---|---|---|---|
| 1 | Coby Health | Visit |
Detailed Reviews
Coby Health
Best for: compounded semaglutide at $159/month
Coby Health LLC runs a direct-to-consumer telehealth marketplace out of Chicago and Springfield, IL, with a BBB file opened 3/2025. Compounded semaglutide starts at $99/mo and compounded tirzepatide at $179/mo, both on a 6-mo bundle at the 0.25mg and 2.5mg starting doses. There is no membership fee. It is LegitScript Certified (seal 38387067), and clinical care runs through Beluga Health P.A., part of the Dr. Jonah Mink network. It does not publicly disclose its compounding pharmacy partners.
Score Breakdown
Frequently Asked Questions
Sources & methodology — as of November 2026
- 1.GLP Watchdog — GLP-1 Pricing Index 2026 (our independent dataset)— GLP Watchdog.
- 2.SURMOUNT-1 Trial — Tirzepatide Once Weekly for the Treatment of Obesity (Jastreboff AM et al.)— New England Journal of Medicine.PMID: 35658024.
- 3.SURMOUNT-5 Trial — Tirzepatide vs. Semaglutide Head-to-Head in Obesity (Aronne LJ et al.)— New England Journal of Medicine.PMID: 40353578.